Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) is a clinical-stage biopharmaceutical company pioneering novel treatments for sight-threatening eye diseases. This news hub provides investors and healthcare professionals with timely updates on OCS's therapeutic advancements in ophthalmology.
Access official press releases and curated analysis covering clinical trial developments, regulatory milestones, and strategic partnerships. Our repository includes updates on key pipeline assets like OCS-01 for diabetic macular edema and OCS-02 for dry eye disease, along with neuro-ophthalmology innovations.
Stay informed about critical events including Phase trial results, FDA communications, licensing agreements, and scientific conference presentations. All content is verified through primary sources to ensure accuracy in this complex regulatory landscape.
Bookmark this page for streamlined tracking of Oculis's progress in developing precision therapies for retinal disorders and ocular surface diseases. Check regularly for material updates that could impact understanding of the company's clinical and commercial potential.
Oculis reported its Q1 2024 financial results and provided updates on its clinical programs, including the initiation of the second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema and completion of enrollment in OCS-02 Phase 2b RELIEF trial in Dry Eye Disease. The company raised $59 million in a direct equity offering, listed on Nasdaq Iceland Main Market, and strengthened its executive team. Financially, Oculis had a cash position of CHF 79.9 million, with research and development expenses of CHF 10.9 million. The company reported a net loss of CHF 16.1 million for Q1 2024. Oculis is on track with its clinical milestones, with topline results anticipated in the second and fourth quarters of 2024.
Oculis has completed enrollment in the Phase 2 ACUITY trial for OCS-05 in patients with Acute Optic Neuritis, with topline results expected in Q4 2024. The drug has received orphan drug designation in the US and Europe for AON. The trial aims to assess the safety and tolerability of OCS-05, offering potential neuroprotective benefits in ophthalmic diseases.
Oculis Holding AG has published an invitation to its 2024 Annual General Meeting, scheduled for May 29, 2024, in Zug, Switzerland. The meeting details and materials are available on the company's website.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) announced that its management will be presenting at the Bank of America Healthcare Conference in Las Vegas on May 14-16, 2024. Riad Sherif, M.D., the CEO, will deliver a company presentation on May 15th at 11:20 am PT. Interested investors can schedule one-on-one meetings through their Bank of America representative.
Oculis Holding AG has published an invitation to its 2024 Annual General Meeting to be held on May 29, 2024, in Zug, Switzerland. The meeting details and materials are available on the company's website.
FAQ
What is the current stock price of Oculis Holding (OCS)?
What is the market cap of Oculis Holding (OCS)?
